With headache being one of the most common chief complaints, it is essential for pain practitioners to interpret and differentiate a variety of headache characteristics to accurately diagnose and treat specific headache disorders. Certain misconceptions often lead to misdiagnosis. This article presents and discusses six myths about several common headache disorders (migraine, tension-type headache, cluster headache, cervicogenic headache, sinus headache, and occipital neuralgia) often encountered in clinical practice. The discussion is based primarily on the International Classification of Headache Disorders, 3rd edition and the latest studies. Recognizing and understanding the intricacies behind key headache diagnoses will help providers devise appropriate plans to better care for their patients.
- tension-type headache
- cluster headache
- cervicogenic headache
- occipital neuralgia
Data availability statement
No data are available.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @ShaliniShahMD, @NatSchusterMD
Contributors HY and SS contributed to conception and design. HY, SS, CY, SA, GC, AP, SS and NMS contributed to acquisition of data. HY, SS, CY, SA, GC, AP, SS and NMS contributed to drafting the article. HY, SS, CY, SA, GC, AP, SS and NMS contributed to revision for intellectual content. NMS contributed to final approval of completed article.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests Within the past 24 months, HY has received funding from NIH (R44NS115460); institutional support for serving as an investigator from Teva, Abbvie, Trillen, Thermaquil; consultant fees from Salvia, Pfizer, Cerenovus; and royalties from Cambridge University Press and MedLink. NS has received compensation from Eli Lilly & Co., Averitas, ShiraTronics, Syneos, Schedule 1 Therapeutics, and Vectura Fertin and research funding from Migraine Research Foundation, Novaremed, UCSD Academic Senate, UCSD Department of Anesthesiology RAG, and NIH CTSA Grant UL1TR000100. SS received consulting honorarium from Allergan.
Provenance and peer review Not commissioned; externally peer reviewed.